ArticleArthritis research & therapy2026
Effects of anti-CD19 CAR-T cells in a murine model of IgG4-related disease.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of IgG4-Related Disease.Current rheumatology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundChimeric antigen receptor T-cell (CAR-T) therapy, an emerging immunotherapy, has shown promising efficacy in several autoimmune diseases. In this study, we conducted a preclinical evaluation of the therapeutic potential of CD19-specific CAR-T cell–mediated B-cell depletion in a mouse model that recapitulates key features of human IgG4-related disease (IgG4-RD).
methodsB cell depletion strategies were evaluated in the LatY136F mouse model, a spontaneous murine model of IgG4-RD. Anti-CD19 CAR-T cells or control cells were transferred into LatY136F mice pretreated with total body irradiation. LatY136F mice treated with anti-CD20 monoclonal antibodies (mAb) served as the positive control group.
resultsCD19-targeted CAR-T cell infusion resulted in a more profound depletion of B cells and plasmablasts compared to anti-CD20 mAb treatment. This depletion was observed in peripheral blood, spleen, lacrimal glands, lungs, and pancreas in LatY136F mice. Moreover, CAR-T cell therapy significantly prolonged the survival of LatY136F mice and improved clinical symptoms compared to anti-CD20 mAb treatment. However, while CAR-T cell therapy reduced inflammation and fibrosis in the lacrimal glands and pancreas, it did not improve these conditions in the lungs.
conclusionsOur findings demonstrate that anti-CD19 CAR-T therapy effectively alleviates the progression of IgG4-RD, showing superior efficacy compared to anti-CD20 mAb in this preclinical model. These results support further investigation of CAR-T cells as a potential therapeutic option for IgG4-RD patients, with attention to potential adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.